ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods

Sandra Weintraub; Tatiana Karpouzian-Rogers; John Devin Peipert; Cindy Nowinski; Jerry Slotkin; Katy Wortman; Emily Ho; Emily Rogalski; Cynthia Carlsson; Bruno Giordani; Felicia Goldstein; John Lucas; Jennifer J. Manly; Dorene Rentz; David Salmon; Beth Snitz; Hiroko H. Dodge; Michaela Riley; Fatima Eldes; Vitali Ustsinovich; Richard Gershon

doi:10.1002/alz.12497

ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods

Sandra Weintraub, Tatiana Karpouzian-Rogers, John Devin Peipert, Cindy Nowinski, Jerry Slotkin, Katy Wortman, Emily Ho, Emily Rogalski, Cynthia Carlsson, Bruno Giordani, Felicia Goldstein, John Lucas, Jennifer J. Manly, Dorene Rentz, David Salmon, Beth Snitz, Hiroko H. Dodge, Michaela Riley, Fatima Eldes, Vitali UstsinovichRichard Gershon

Psychology

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: Early detection of cognitive decline in older adults is a public health priority. Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging (ARMADA), a multisite study, is validating cognition, emotion, motor, and sensory modules of the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function (NIHTB) in the aging spectrum from cognitively normal to dementia of the Alzheimer's type (DAT). Methods: Participants 65 to 85 years old, in demographic groups racially proportional to the general US population, are recruited in one of three groups to validate the NIHTB: cognitively normal, amnestic mild cognitive impairment (aMCI), or mild DAT. Additional special emphasis cohorts include (1) Blacks in the three clinical groups; (2) Spanish-speakers in the three clinical groups; (3) cognitively normal, population-proportional, over age 85. Discussion: Longitudinal study will determine whether NIHTB can predict cognitive decline and is associated with Alzheimer's disease biomarkers. Here, we detail the methods for the ARMADA study.

Original language	English (US)
Pages (from-to)	1449-1460
Number of pages	12
Journal	Alzheimer's and Dementia
Volume	18
Issue number	8
DOIs	https://doi.org/10.1002/alz.12497
State	Published - Aug 2022

Keywords

Alzheimer's disease
NIH Toolbox
cognition
dementia
mild cognitive impairment
neuropsychology

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Cellular and Molecular Neuroscience
Psychiatry and Mental health

Access to Document

10.1002/alz.12497

Cite this

Weintraub, S., Karpouzian-Rogers, T., Peipert, J. D., Nowinski, C., Slotkin, J., Wortman, K., Ho, E., Rogalski, E., Carlsson, C., Giordani, B., Goldstein, F., Lucas, J., Manly, J. J., Rentz, D., Salmon, D., Snitz, B., Dodge, H. H., Riley, M., Eldes, F., ... Gershon, R. (2022). ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods. Alzheimer's and Dementia, 18(8), 1449-1460. https://doi.org/10.1002/alz.12497

Weintraub, S, Karpouzian-Rogers, T, Peipert, JD, Nowinski, C, Slotkin, J, Wortman, K, Ho, E, Rogalski, E, Carlsson, C, Giordani, B, Goldstein, F, Lucas, J, Manly, JJ, Rentz, D, Salmon, D, Snitz, B, Dodge, HH, Riley, M, Eldes, F, Ustsinovich, V & Gershon, R 2022, 'ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods', Alzheimer's and Dementia, vol. 18, no. 8, pp. 1449-1460. https://doi.org/10.1002/alz.12497

@article{e84ac0bb2cc74dbeae6d6c86b2d0d94e,

title = "ARMADA: Assessing reliable measurement in Alzheimer{\textquoteright}s disease and cognitive aging project methods",

abstract = "Introduction: Early detection of cognitive decline in older adults is a public health priority. Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging (ARMADA), a multisite study, is validating cognition, emotion, motor, and sensory modules of the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function (NIHTB) in the aging spectrum from cognitively normal to dementia of the Alzheimer's type (DAT). Methods: Participants 65 to 85 years old, in demographic groups racially proportional to the general US population, are recruited in one of three groups to validate the NIHTB: cognitively normal, amnestic mild cognitive impairment (aMCI), or mild DAT. Additional special emphasis cohorts include (1) Blacks in the three clinical groups; (2) Spanish-speakers in the three clinical groups; (3) cognitively normal, population-proportional, over age 85. Discussion: Longitudinal study will determine whether NIHTB can predict cognitive decline and is associated with Alzheimer's disease biomarkers. Here, we detail the methods for the ARMADA study.",

keywords = "Alzheimer's disease, NIH Toolbox, cognition, dementia, mild cognitive impairment, neuropsychology",

author = "Sandra Weintraub and Tatiana Karpouzian-Rogers and Peipert, {John Devin} and Cindy Nowinski and Jerry Slotkin and Katy Wortman and Emily Ho and Emily Rogalski and Cynthia Carlsson and Bruno Giordani and Felicia Goldstein and John Lucas and Manly, {Jennifer J.} and Dorene Rentz and David Salmon and Beth Snitz and Dodge, {Hiroko H.} and Michaela Riley and Fatima Eldes and Vitali Ustsinovich and Richard Gershon",

note = "Publisher Copyright: {\textcopyright} 2021 the Alzheimer's Association.",

year = "2022",

month = aug,

doi = "10.1002/alz.12497",

language = "English (US)",

volume = "18",

pages = "1449--1460",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - ARMADA

T2 - Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods

AU - Weintraub, Sandra

AU - Karpouzian-Rogers, Tatiana

AU - Peipert, John Devin

AU - Nowinski, Cindy

AU - Slotkin, Jerry

AU - Wortman, Katy

AU - Ho, Emily

AU - Rogalski, Emily

AU - Carlsson, Cynthia

AU - Giordani, Bruno

AU - Goldstein, Felicia

AU - Lucas, John

AU - Manly, Jennifer J.

AU - Rentz, Dorene

AU - Salmon, David

AU - Snitz, Beth

AU - Dodge, Hiroko H.

AU - Riley, Michaela

AU - Eldes, Fatima

AU - Ustsinovich, Vitali

AU - Gershon, Richard

PY - 2022/8

Y1 - 2022/8

N2 - Introduction: Early detection of cognitive decline in older adults is a public health priority. Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging (ARMADA), a multisite study, is validating cognition, emotion, motor, and sensory modules of the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function (NIHTB) in the aging spectrum from cognitively normal to dementia of the Alzheimer's type (DAT). Methods: Participants 65 to 85 years old, in demographic groups racially proportional to the general US population, are recruited in one of three groups to validate the NIHTB: cognitively normal, amnestic mild cognitive impairment (aMCI), or mild DAT. Additional special emphasis cohorts include (1) Blacks in the three clinical groups; (2) Spanish-speakers in the three clinical groups; (3) cognitively normal, population-proportional, over age 85. Discussion: Longitudinal study will determine whether NIHTB can predict cognitive decline and is associated with Alzheimer's disease biomarkers. Here, we detail the methods for the ARMADA study.

AB - Introduction: Early detection of cognitive decline in older adults is a public health priority. Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging (ARMADA), a multisite study, is validating cognition, emotion, motor, and sensory modules of the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function (NIHTB) in the aging spectrum from cognitively normal to dementia of the Alzheimer's type (DAT). Methods: Participants 65 to 85 years old, in demographic groups racially proportional to the general US population, are recruited in one of three groups to validate the NIHTB: cognitively normal, amnestic mild cognitive impairment (aMCI), or mild DAT. Additional special emphasis cohorts include (1) Blacks in the three clinical groups; (2) Spanish-speakers in the three clinical groups; (3) cognitively normal, population-proportional, over age 85. Discussion: Longitudinal study will determine whether NIHTB can predict cognitive decline and is associated with Alzheimer's disease biomarkers. Here, we detail the methods for the ARMADA study.

KW - Alzheimer's disease

KW - NIH Toolbox

KW - cognition

KW - dementia

KW - mild cognitive impairment

KW - neuropsychology

UR - http://www.scopus.com/inward/record.url?scp=85119058954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119058954&partnerID=8YFLogxK

U2 - 10.1002/alz.12497

DO - 10.1002/alz.12497

M3 - Article

C2 - 34786833

AN - SCOPUS:85119058954

SN - 1552-5260

VL - 18

SP - 1449

EP - 1460

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 8

ER -

ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this